The results, however, do not suggest that sorafenib is the second-line agent of choice, rather solidified the hypothesis that angiogenic escape is in fact one of the mechanisms resistant to first-line VEGFR inhibition, and thus, the possibility that sequential VEGF-based therapy is a logical treatment strategy in patients with advanced RCC. Here, VEGFA is linked to renal cell carcinoma.